Latanoprost Sandoz

Latanoprost, the active ingredient in Latanoprost Sandoz, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It treats open‑angle glaucoma and ocular hypertension in adults by lowering intra‑ocular pressure.

GNH USA supplies Latanoprost Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Elevated intra‑ocular pressure (IOP): helps achieve target pressure levels in at‑risk patients.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash length and density. - Darkening of the iris pigment. - Eye irritation or foreign‑body sensation. - Blurred vision shortly after instillation. - Mild ocular itching.

Serious or Rare Side Effects: - Severe eye inflammation (uveitis or iritis). - Allergic reactions such as swelling of the eyelids or face. - Sudden loss of vision. - Ocular infection. - Systemic hypersensitivity reactions. - Persistent changes in visual acuity.

Before initiating therapy, clinicians should evaluate ocular health and monitor patients regularly.

Baseline IOP measurement: record intra‑ocular pressure prior to first use. Monitor iris pigmentation: watch for gradual darkening of the iris. Avoid use in active ocular infection: postpone treatment until infection resolves. Caution in corneal disorders: assess corneal health before prescribing. Consider asthma history: prostaglandin analogs may exacerbate bronchospasm. Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analog eye drops: may cause additive ocular effects. - Use with non‑steroidal anti‑inflammatory eye drops: can diminish pressure‑lowering response. - Simultaneous administration of multiple intra‑ocular pressure‑lowering agents without supervision: risk of excessive pressure reduction.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may counteract pressure‑lowering effect. - Beta‑blocker eye drops: potential pharmacodynamic interaction affecting IOP control. - Systemic antihistamines: may influence ocular surface tolerance.